Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus Europe
3:10 – 3:35 pm
Bacterial contamination rate of platelet components by primary culture and residual risk associated with false negatives: results from two recent meta-analyses
Ryan A. Metcalf | Medical Director, Blood Bank Assistant Professor; Inpatient Chief Value Officer; Department of Pathology | University of Utah and ARUP Laboratories
Multiple individual studies have reported bacterial contamination rates for both whole blood and apheresis platelet collections. Based on a systematic review of published data and meta-analysis best estimates of bacterial contamination rates were obtained for apheresis, platelet rich plasma and buffy coat collection methods. The impact of collection method, sample volume, positivity criteria, and study date on the bacterial contamination rate was determined. A second systematic review and meta-analysis evaluated risk associated with false negative primary culture results.
3:35 - 4:00 pm
Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported?
Richard Benjamin | Chief Medical Officer | Cerus Global Headquarters
Contaminated platelets are often transfused, yet septic reactions are reported infrequently.
Are contaminated platelets that do not cause sepsis clinically relevant? Why do septic transfusion reactions often go unnoticed? What are the reasons that only a minority of suspected reactions reported by hospitals are confirmed and are reported in official hemovigilance reports?
4:00 – 4:15 pm
Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus
1220 Concord Avenue
Concord, CA US 94520
3811 MH Amersfoort, Netherlands
+31 (0)33 49 60 600
Copyright 2021, CERUS. All rights reserved. MKT-EN 00477-14, v3.0
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. Follow us on LinkedIn.